Skip to main content

Advertisement

SpringerLink
Log in

Antifungal Stewardship in Low- and Middle-Income Countries

  • Infection Prevention and Safety in Low and Middle Income Countries (AC Barossy, Section Editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Abstract

Purpose of review

Antifungal stewardship refers to coordinated interventions designed to improve and measure the appropriate use of antifungals by promoting the selection of the optimal antifungal drug regimen, dose, duration of therapy, and route of administration.

Recent findings

The high mortality associated with invasive fungal diseases (IFDs), combined with suboptimal diagnostic tools, has driven the overuse of antifungal drugs. High drug costs and the toxicities of antifungal agents are the principal rationale for antifungal stewardship, while antifungal resistance is an emerging but less prevalent issue.

Summary

This review assesses the situation of antifungal stewardship in low- and middle-income countries and provides basic tools for the development of antifungal stewardship (AFS) programs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77 This document establishes the main guidelines for AMS.

    Article  PubMed  Google Scholar 

  2. • Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis. 2012;25:107–15. A good revision of anti fungal stewardship.

    Article  PubMed  Google Scholar 

  3. Global Action Fund for Fungal Infections (GAFFI). Hidden crisis. June 2016. Website: https://www.gaffi.org/wp-content/uploads/GAFFI-Leaflet-June-2016-DWD-hidden-crisis.pdf. Accessed 27 Dec 2019.

  4. •• Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG. White TC hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13 This review highlights the importance of fungi as human pathogens and discusses the challenges in combating the devastating invasive infections.

    Article  CAS  PubMed  Google Scholar 

  5. Valerio M, Rodriguez-Gonzalez CG, Muñoz P, Caliz B, Sanjurjo M, Bouza E, et al. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother. 2014;69(7):1993–9. https://doi.org/10.1093/jac/dku053.

  6. Berger S, El Chazli Y, Babu AF, Coste AT. Azole resistance in Aspergillus fumigatus: a consequence of antifungal use in agriculture? Front Microbiol. 2017;8(1024). https://doi.org/10.3389/fmicb.2017.01024.

  7. WHO Antimicrobial resistance: global report on surveillance. 2014. Available from: http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 21 Aug 2017

  8. Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2016;64:134–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bizerra FC, Jimenez-Ortigosa C, Souza ACR, Breda GL, Queiroz-Telles F, Perlin DS, et al. Breakthrough candidemia due to multidrug resistant C. glabrata during prophylaxis with low dose of micafungin. Antimicrob Agents Chemother. 2014;58:2438–40. https://doi.org/10.1128/AAC-02189-13.

  10. •• Muñoz P, Valerio M, Vena A, Bouza E. Antifungal stewardship in daily practice and health economic implications. Mycoses. 2015;58:14–25. https://doi.org/10.1111/myc.12329 Review the available evidence for the use of AFS and their impact on health economics.

    Article  PubMed  Google Scholar 

  11. •• Kneale M, Bartholomew JS, Davies E, Denning DW. Global access to antifungal therapy and its variable cost. J Antimicrob Chemother. 2016;71(12):3599–606. https://doi.org/10.1093/jac/dkw325 Offer a map by country systemic generic antifungal drug registration.

    Article  CAS  PubMed  Google Scholar 

  12. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health. 2002;5(1):26–34.

    Article  PubMed  Google Scholar 

  13. Gedik H. The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis. Clinicoecon Outcomes Res. 2015;7:537–43. https://doi.org/10.2147/CEOR.S92455.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses. 2010;54:e301–12.

    Article  PubMed  Google Scholar 

  15. Laundry M, Gilchrist M, Laura W. Antimicrobial stewardship. 1st ed. Oxford: Oxford University Press; 2016. Chap. 16

  16. Andes D, Azie N, Yang H, Harrington R, Kelley C, Tan RD, et al. Drug-drug interaction associated with mold-active triazoles among hospitalized patients. Antimicrob Agents Chemother. 2016;60(6):3398–406. https://doi.org/10.1128/AAC.00054-16.

  17. Valerio M, Munoz P, Zamora E, Salcedo M, Verde E, Bustinza A, et al. Stewardship in antifungals. How much do prescribing physicians know? Oral presentation at the 21st ECCMID/27th ICC. Clin Microbiol Infect. 2011;17(Suppl. 4:S35.

    Google Scholar 

  18. Pasqualotto AC, Quieroz-Telles F. Histoplasmosis dethrones tuberculosis in Latin America. Lancet Infect Dis. 2018;18:1058–60. https://doi.org/10.1016/S1473-3099(18)30373-6.

    Article  PubMed  Google Scholar 

  19. Falci DR, Stadnik CMB, Pasqualotto AC. A review of diagnostic methods for invasive fungal diseases: challenges and perspectives. Infect Dis Ther. 2017;6(2):213–23. https://doi.org/10.1007/s40121-017-0154-1.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Valerio M, Vena A, Bouza E, Reiter N, Viale P, Hochreiter M, et al. How much European prescribing physicians know about invasive fungal infections management? BMC Infect Dis. 2015;15:80. https://doi.org/10.1186/s12879-015-0809-z.

  21. Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011;66:2146–51.

  22. VU B. The time for antifungal stewardship programs is now; 2017. Retrieved from. https://www.contagionlive.com/publications/contagion/2017/november2017/the-time-for-antifungal-stewardship-programs-is-now?p=2. Accessed 27 Dec 2019.

  23. Falci D, Pasqualotto A. 417. Clinical mycology in Latin America and the Caribbean: diagnostic capabilities and antifungal therapy. Open Forum Infect Dis. 2018;5(suppl_1):S159. https://doi.org/10.1093/ofid/ofy210.428.

    Article  PubMed Central  Google Scholar 

  24. Kozel TR, Wickes B. Fungal diagnostics. CSH Perspect Med. 2014;4(4):a019299. https://doi.org/10.1101/cshperspect.a019299.

    Article  CAS  Google Scholar 

  25. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49(9):3640–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Muñoz P, Bouza E. COMIC (Collaboration Group on Mycosis) study group. The current treatment landscape: the need for antifungal stewardship programmes. J Antimicrob Chemother. 2016;71(suppl(2):ii5–ii12.

    Article  PubMed  Google Scholar 

  27. •• Agrawal S, Barnes R, Brüggemann RJ, Rautemaa-Richardson R, Warris A. The role of the multidisciplinary team in antifungal stewardship. J Antimicrob Chemother. 2016;71(suppl 2):ii37–42 Description of the specific roles of the key individuals within the AFS team and the importance of collaboration are discussed in this article.

    Article  PubMed  Google Scholar 

  28. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–e50. https://doi.org/10.1093/cid/civ933.

  29. Colombo AL, Guimarães T, Camargo LF, Richtmann R, Queiroz-Telles FD, Salles MJ, et al. Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina tropical. Braz J Infect Dis. 2013;17(3):283–312. https://doi.org/10.1016/j.bjid.2013.02.001.

  30. Riera F, Thompson L, Celi A. Manual Practico de Infecciones Fungicas. 2nd ed. Quito: Asociación Panamericana de Infectología; 2017. http://www.apinfectologia.com/proyectos/. Accessed 27 Dec 2019.

  31. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. https://doi.org/10.1093/cid/ciw326.

  32. Des Champs-Bro B, Leroy-Cotteau A, Mazingue F, et al. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco- haematology. J Clin Pharm Ther. 2011;36:152–60.

    Article  CAS  PubMed  Google Scholar 

  33. Murakami M, Komatsu H, Sugiyama M, Ichikawa Y, Ide K, Tsuchiya R, et al. Antimicrobial stewardship without infectious disease physician for patients with candidemia: a before and after study. J Gen Fam Med. 2018;19(3):82–9. https://doi.org/10.1002/jgf2.159.

  34. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(42). https://doi.org/10.1186/1748-5908-6-42.

  35. Valerio M, Munõz P, Rodríguez-González C, Sanjurjo M, Guinea J, Bouza E, et al. Training should be the first step toward an antifungal stewardship program. Enferm Infecc Microbiol Clin. 2015;33:221–7.

    Article  PubMed  Google Scholar 

  36. Wattal C, Chakrabarti A, Oberoi JK, Donnelly JP, Barnes RA, Sherwal BL, et al. Issues in antifungal stewardship: an opportunity that should not be lost. J Antimicrob Chemother. 2017;72(4):969–74. https://doi.org/10.1093/jac/dkw506.

Download references

Author information

Authors and Affiliations

  1. Sanatorio Allende Argentina, National University of Córdoba, Córdoba, Argentina

    Fernando Riera MD

  2. Hospital Privado Universitario de Córdoba, Córdoba, Argentina

    Juan Pablo Caeiro MD

  3. National University of Córdoba, Córdoba, Argentina

    Juan Pablo Caeiro MD

  4. Laboratorio de Inmunidad Innata a Patógenos Fúngicos, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología, CIBICI-CONICET, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina

    Claudia Elena Sotomayor PHD

Authors
  1. Fernando Riera MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan Pablo Caeiro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudia Elena Sotomayor PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernando Riera MD.

Ethics declarations

Conflict of Interest

Dr. Fernando Riera has received educational grants from Merck, Gilead, and TEVA.

Juan Pablo Caeiro declares that he has no conflict of interest.

Claudia Elena Sotomayor declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Infection Prevention and Safety in Low and Middle Income Countries

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Riera, F., Caeiro, J.P. & Sotomayor, C.E. Antifungal Stewardship in Low- and Middle-Income Countries. Curr Treat Options Infect Dis 11, 292–299 (2019). https://doi.org/10.1007/s40506-019-00197-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-019-00197-2

Keywords

Search

Navigation